Pablo Sarobe

ResearcherID Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Venues

Human vaccines & immunotherapeutics

Cancers

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

Fundación para la Investigación Médica Aplicada/Universidad de Navarra

Universidad de Navarra (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fundación para la Investigación Médica Aplicada/Universidad de Navarra

Spain

Investigador :: Programa de Inmunología e Inmunoterapia

Universidad de Navarra

Spain

Investigador :: Medicina Interna

National Institutes of Health

United States

Guest Researcher :: NCI

Universidad de Navarra

Spain

Becario post-doctoral :: Medicina Interna

Universidad de Navarra

Spain

Becario predoctoral :: Medicina Interna

Education History

Universidad de Navarra

Spain

PHD :: Departamento de Medicina Interna

Publications

Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren, Jose-Luis Perez-Gracia, Javier Rodríguez Rodríguez, Jaime Gállego Pérez-Larraya, Pablo Sarobe, Susana Inogés, Ascensión López Díaz de Cerio, Marta Santisteban
Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers 16 (5) (2024)
Belen Aparicio, Patrick Theunissen, Sandra Hervas-Stubbs, Puri Fortes, Pablo Sarobe
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies. Human vaccines & immunotherapeutics 20 (1) (2024)
Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren, Jose-Luis Perez-Gracia, Javier Rodríguez Rodríguez, Jaime Gállego Pérez-Larraya, Pablo Sarobe, Susana Inogés, Ascensión López Díaz de Cerio, Marta Santisteban
Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers 16 (5) (2024)
Belen Aparicio, Patrick Theunissen, Sandra Hervas-Stubbs, Puri Fortes, Pablo Sarobe
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies. Human vaccines & immunotherapeutics 20 (1) (2024)
Belen Aparicio, Patrick Theunissen, Sandra Hervas-Stubbs, Puri Fortes, Pablo Sarobe
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies. Human vaccines & immunotherapeutics 20 (1) (2024)
Francisco Javier Cubero, Pablo Sarobe, Gisa Tiegs
Advancing with cancer immunotherapeutics: CD29 + regulatory T cell antagonism. Gut (2023)
David Repáraz, Belén Aparicio, Diana Llopiz, Sandra Hervás-Stubbs, Pablo Sarobe
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? International journal of molecular sciences 23 (4) (2022)
David Repáraz, Marta Ruiz, Diana Llopiz, Leyre Silva, Enric Vercher, Belén Aparicio, Josune Egea, Ibon Tamayo-Uria, Sandra Hervás-Stubbs, Jorge García-Balduz, Carla Castro, Mercedes Iñarrairaegui, Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Luigi Buonaguro, Charlotte Rohrer, Kathrin Heim, Catrin Tauber, Maike Hofmann, Robert Thimme, Bruno Sangro, Pablo Sarobe
Neoantigens as potential vaccines in hepatocellular carcinoma. Journal for immunotherapy of cancer 10 (2) (2022)
Belén Aparicio, Noelia Casares, Josune Egea, Marta Ruiz, Diana Llopiz, Sheila Maestro, Cristina Olagüe, Gloria Gonzalez Aseguinolaza, Cristian Smerdou, Ascensión López-Díaz de Cerio, Susana Inogés, Felipe Prosper, José Ramón Yuste, Francisco Carmona-Torre, Gabriel Reina, Juan Jose Lasarte, Pablo Sarobe
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging microbes & infections 10 (1) (2021)
Bruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, Ignacio Melero Bermejo
Advances in immunotherapy for hepatocellular carcinoma. Nature reviews. Gastroenterology & hepatology 18 (8) (2021)
Laura Arribillaga, Iciar Echeverria, Viriginia Belsue, Timothy Gomez, Teresa Lozano, Noelia Casares, Lorea Villanueva, Sonia Domingos-Pereira, Pedro J Romero, Denise Nardelli-Haefliger, Sandra Hervás-Stubbs, Pablo Sarobe, María Josefa Rodriguez, José L Carrascosa, Thomas Zürcher, Juan Jose Lasarte
Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. Journal for immunotherapy of cancer 8 (1) (2021)
Diana Llopiz, Marta Ruiz, Lorea Villanueva, Tamara Iglesias, Leyre Silva, Josune Egea, Juan Jose Lasarte, Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur, Graham Dixon, Bruno Sangro, Pablo Sarobe
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer immunology, immunotherapy : CII 68 (3) (2018)

Pablo Sarobe.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pablo Sarobe